Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer
Kairos Pharma, Ltd. (KAPA)
Company Research
Source: Business Wire
Company recognized for advancing ENV-105, a first-in-class resistance-modulating antibody for metastatic castration-resistant prostate cancer LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announced that it has been selected as a winner of the 2025 Clinical Trials Arena Excellence Awards, receiving the Research and Development Award for Advanced Prostate Cancer.Kairos earned this recognition for its work advancing ENV-105 (carotuximab), a first-in-class CD105-targeting monoclonal antibody designed to modulate resistance pathways in metastatic castration-resistant prostate cancer (mCRPC). ENV-105 is being developed as a resistance-focused therapy intended to restore and extend tumor sensitivity to hormone-based treatments in patients whose disease has progressed after standard androgen receptor inhibitor therapy.This year, Kairos announced positive interim safety and
Show less
Read more
Impact Snapshot
Event Time:
KAPA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KAPA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KAPA alerts
High impacting Kairos Pharma, Ltd. news events
Weekly update
A roundup of the hottest topics
KAPA
News
- Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer [Yahoo! Finance]Yahoo! Finance
- Kairos Pharma Provides Shareholder UpdateBusiness Wire
- Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) MeetingBusiness Wire
- Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025 [Yahoo! Finance]Yahoo! Finance
- Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025Business Wire
KAPA
Sec Filings
- 12/23/25 - Form 4
- 11/26/25 - Form 4
- 11/26/25 - Form 4
- KAPA's page on the SEC website